Glaxosmithkline Pharmaceuticals Ltd.

NSE: GLAXO · Healthcare

₹2,524.80+0.98%06 Nov 2026

Ask the data

Instant answers about Glaxosmithkline Pharmaceuticals Ltd. — computed from its filings, no language model

Market cap₹42,773 cr

Current price₹2,524.80

High / Low₹3,106 / ₹2,103

P/E83.0

P/B22.74

Book value₹111.0

ROE27.4%

ROCE82.8%

Debt / equity0.00

Dividend yield1.67%

EPS (TTM)₹30.40

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY20	FY21	FY22	FY23	FY24	FY26
Revenue	3,224	3,199	3,278	3,252	3,454	3,822
EBITDA	657	695	762	804	909	1,309
Operating margin	20.4%	21.7%	23.2%	24.7%	26.3%	34.3%
Interest	6	4	2	2	2	3
Depreciation	83	79	68	66	70	66
Profit before tax	306	550	779	836	816	1,406
Tax	213	192	398	229	226	370
Net profit	93	358	1,695	611	590	1,036
EPS ₹	5.50	21.14	100.04	36.05	34.83	54.52
Operating cash flow	—	—	811	484	582	903
Capex	—	—	35	44	31	55
Dividend paid	—	—	507	1,526	542	714
Total assets	3,133	3,115	4,633	3,327	3,557	4,324
Equity	1,821	1,478	2,663	1,741	1,778	2,267

Quarterly performance

last 28 quarters · ₹ crore

showing latest 8 of 28 periods

	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	788	882	779	776	649	879	857	814	790	1,010	816	810	917	802	787	762	957	805	930	815	1,011	949	805	980	1,041	995	938	1,184
Operating profit	165	194	124	174	114	205	206	171	152	277	198	175	257	229	170	144	289	218	257	231	322	292	251	336	371	351	296	402
Operating margin	21.0%	22.0%	16.0%	22.4%	17.6%	23.3%	24.0%	21.0%	19.2%	27.4%	24.2%	21.6%	28.0%	28.5%	21.6%	18.9%	30.3%	27.1%	27.7%	28.3%	31.8%	30.7%	31.2%	34.3%	35.7%	35.3%	31.5%	34.0%
Other income	31	16	16	16	58	9	14	30	32	15	10	19	22	23	28	36	28	28	30	36	35	35	44	34	32	36	44	73
Interest	1	1	3	2	1	1	1	1	1	0	1	0	0	0	1	0	0	0	1	0	0	0	0	1	1	1	1	0
Depreciation	19	23	18	23	22	22	18	18	18	18	18	15	16	16	17	16	18	17	18	16	17	19	16	17	20	13	16	15
Profit before tax	176	587	-634	177	149	127	211	63	165	274	172	208	262	224	190	181	299	65	271	249	344	308	279	354	400	373	322	459
Tax	63	85	27	38	38	50	55	49	44	69	33	263	69	60	57	49	82	20	76	67	91	78	74	97	104	95	85	123
Net profit	114	503	-661	138	111	76	157	14	121	204	150	1,219	193	165	133	132	218	46	194	0	252	230	0	0	0	278	237	0
EPS ₹	6.70	29.68	-39.03	8.15	6.54	4.51	9.24	0.85	7.15	12.06	8.88	71.96	11.42	9.71	7.88	7.04	12.84	9.89	11.48	10.76	14.67	13.57	12.10	15.07	16.54	16.40	14.00	19.83
Revenue YoY	—	—	—	—	-17.7%	-0.3%	10.1%	4.9%	21.8%	14.8%	-4.8%	-0.5%	-9.2%	-1.7%	-2.7%	—	4.4%	0.4%	18.1%	7.0%	5.6%	17.9%	-1.2%	-3.1%	9.7%	—	16.6%	20.8%
Profit YoY	—	—	—	—	-2.4%	-84.8%	—	-89.6%	9.2%	167.1%	-3.9%	8407.0%	-5.3%	9.5%	-89.1%	—	12.5%	-72.2%	45.8%	-100.0%	16.1%	402.8%	—	-100.0%	-100.0%	—	—	—

Earlier results (standalone, Sep '07 – Mar '19)

₹ crore · from BSE, before the NSE XBRL filings begin

Glaxosmithkline Pharmaceuticals Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 11 periods

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†	FY18†	FY19†
Revenue	1,716	1,977	2,207	2,396	2,637	2,519	2,678	2,757	2,995	2,896	3,129
Operating profit	637	712	782	767	784	462	520	477	420	508	606
Operating margin	37.1%	36.0%	35.4%	32.0%	29.7%	18.3%	19.4%	17.3%	14.0%	17.6%	19.4%
Other income	63	—	—	—	197	169	154	122	72	54	101
Interest	—	76	109	—	—	—	—	—	—	—	1
Depreciation	16	16	18	20	18	20	21	25	26	38	49
Profit before tax	699	808	892	836	906	639	600	577	511	542	664
Tax	100	278	489	283	283	209	225	202	174	190	238
Net profit	599	530	403	553	623	429	375	375	337	352	425

Quarters

showing latest 8 of 47 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†	MAR '18†	JUN '18†	SEP '18†	DEC '18†	MAR '19†
Revenue	421	339	418	417	464	375	461	462	518	450	547	508	589	501	610	574	615	578	630	662	676	663	637	645	627	637	610	660	747	651	620	628	700	736	693	705	799	706	784	607	836	704	749	736	816	825	751
Operating profit	137	102	152	151	207	111	168	167	195	144	206	191	216	157	218	199	183	182	203	213	206	197	168	122	114	118	108	114	165	115	126	110	129	110	129	90	141	52	137	20	192	142	155	140	165	137	164
Operating margin	32.5%	30.2%	36.4%	36.3%	44.6%	29.7%	36.5%	36.2%	37.7%	32.0%	37.6%	37.7%	36.6%	31.4%	35.7%	34.7%	29.8%	31.5%	32.2%	32.1%	30.5%	29.8%	26.3%	18.9%	18.2%	18.6%	17.6%	17.3%	22.1%	17.6%	20.3%	17.5%	18.4%	14.9%	18.6%	12.8%	17.6%	7.4%	17.4%	3.2%	23.0%	20.1%	20.7%	19.1%	20.2%	16.6%	21.8%
Other income	34	29	34	26	10	1	26	18	—	—	18	—	—	—	18	—	—	—	73	38	40	42	77	37	39	48	45	40	36	38	40	40	31	26	24	24	18	15	15	14	10	12	18	18	15	16	52
Interest	—	—	—	—	15	30	—	19	17	19	20	20	26	31	33	30	37	42	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0	0	0	0	0
Depreciation	4	5	4	4	4	5	4	4	4	5	4	4	4	6	4	5	5	6	4	4	5	5	4	5	5	6	4	5	5	6	5	5	5	8	7	5	7	7	8	8	8	13	9	11	12	12	14
Profit before tax	167	126	183	173	198	137	191	201	208	159	240	207	237	182	265	224	215	218	179	237	225	205	239	174	148	169	148	149	195	101	156	143	147	125	162	111	152	78	170	38	199	140	164	138	156	170	199
Tax	-82	45	61	58	66	-72	48	77	67	55	79	78	80	67	264	77	69	81	56	74	73	66	70	59	47	52	52	51	66	55	53	49	51	45	56	39	54	25	57	12	69	51	58	50	56	57	76
Net profit	249	81	121	115	132	208	143	124	141	104	161	129	158	116	0	148	146	137	123	164	152	139	169	115	101	117	97	98	129	45	103	93	96	80	106	72	99	53	113	26	130	90	106	89	101	113	123
EPS ₹	29.40	9.60	14.30	13.60	15.60	24.60	16.90	14.70	16.70	12.20	19.00	15.20	18.60	13.70	0.10	17.40	17.20	16.10	14.50	19.30	18.00	16.40	20.00	13.50	11.90	13.80	11.40	11.60	15.20	5.30	12.10	11.00	11.30	9.40	12.50	8.50	11.70	6.30	13.30	3.10	15.40	10.60	12.46	10.46	5.95	6.67	7.26
Revenue YoY	—	—	—	—	10.2%	10.5%	10.3%	10.8%	11.8%	20.0%	18.6%	9.9%	13.7%	11.3%	11.6%	13.1%	4.3%	15.4%	3.3%	15.3%	10.0%	14.7%	1.1%	-2.5%	-7.3%	-3.8%	-4.2%	2.2%	19.2%	2.1%	1.7%	-4.8%	-6.2%	13.0%	11.7%	12.3%	14.1%	-4.0%	13.1%	-13.9%	4.6%	-0.3%	-4.5%	21.2%	-2.4%	17.3%	0.3%
Profit YoY	—	—	—	—	-47.0%	157.7%	18.1%	8.3%	6.9%	-50.3%	12.5%	3.7%	11.9%	11.7%	-99.7%	14.4%	-7.6%	18.2%	26615.2%	10.8%	4.4%	1.3%	37.5%	-29.6%	-33.7%	-15.6%	-42.9%	-14.6%	27.5%	-61.2%	6.5%	-5.1%	-25.4%	76.4%	3.0%	-22.5%	2.9%	-33.7%	6.4%	-63.4%	31.8%	69.4%	-6.4%	235.3%	-22.7%	26.0%	16.6%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 19 periods

	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '26	JUN '26	SEP '26
ROE	5.1%	5.0%	-18.4%	26.5%	24.2%	24.9%	33.6%	33.1%	63.6%	35.8%	42.1%	34.4%	33.2%	25.7%	29.5%	40.5%	12.3%	22.7%	27.4%
ROCE	17.1%	15.7%	-9.6%	36.7%	37.5%	38.5%	48.4%	45.7%	30.8%	49.3%	58.2%	47.9%	46.0%	49.9%	55.7%	70.2%	62.1%	64.1%	82.8%
Net margin	2.9%	2.9%	-10.9%	15.2%	11.2%	11.0%	14.3%	14.3%	49.5%	19.1%	19.6%	16.0%	17.1%	13.1%	13.8%	18.3%	7.3%	13.0%	12.4%
EBITDA margin	20.4%	19.6%	20.0%	22.1%	21.7%	21.9%	23.2%	23.2%	23.4%	24.5%	25.1%	24.8%	26.3%	28.4%	28.9%	29.7%	34.3%	34.2%	34.1%
Debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest coverage	49.23	43.96	-27.17	151.57	156.95	175.77	264.05	287.47	410.02	609.05	617.80	438.82	454.44	469.05	538.14	782.29	516.02	442.91	477.94
Asset turnover	1.03	0.98	0.98	1.01	1.03	1.07	1.11	1.10	0.74	0.98	1.01	1.01	0.97	0.99	0.95	0.99	0.88	0.91	1.05

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 15 periods

	MAR '14‡	MAR '15‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	SEP '25	MAR '26	SEP '26
Share capital	85	85	85	169	169	169	169	169	169	169	169	169	169	169	169
Other equity / reserves	1,905	1,744	1,973	1,970	1,651	1,309	2,494	1,285	1,572	1,370	1,608	1,503	1,538	2,098	1,712
Total equity	1,990	1,829	2,057	2,140	1,821	1,478	2,663	1,455	1,741	1,540	1,778	1,673	1,708	2,267	1,881
Borrowings	4	3	1	0	0	0	0	0	0	0	0	0	0	0	0
Current liabilities	889	1,107	1,600	1,454	1,022	1,355	1,698	1,295	1,326	1,462	1,525	1,813	1,674	1,779	1,806
Non-current liabilities	251	280	290	317	291	282	272	265	259	269	254	260	284	260	282
Total assets	3,130	3,216	3,947	3,911	3,133	3,115	4,633	3,015	3,327	3,270	3,557	3,746	3,665	4,324	3,969
Property, plant & equipment	100	123	250	364	668	311	277	287	295	288	297	263	282	274	286
Capital work-in-progress	62	115	923	1,003	120	13	30	36	20	26	14	21	17	33	35
Investments	10	0	0	0	—	0	366	549	518	514	813	1,001	1,313	1,392	1,525
Inventories	347	376	500	486	483	547	535	646	460	537	525	518	536	458	554
Receivables	96	100	147	120	100	216	205	166	192	211	222	268	333	273	339
Cash & equivalents	2,042	1,911	201	99	105	405	286	56	35	74	64	49	340	1,102	651

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 10 periods

	FY14‡	FY15‡	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY26
Cash from operations	281	338	473	409	490	578	811	484	582	903
Cash from investing	189	180	-104	-153	-57	418	-406	808	9	397
Cash from financing	-494	-496	-307	-358	-428	-696	-524	-1,543	-561	-737
Capex	—	—	—	—	—	—	35	44	31	55
Free cash flow	—	—	—	—	—	—	776	440	551	848
Dividends paid	421	422	254	296	339	677	507	1,526	542	714

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹286 cr7%

CWIP

₹35 cr1%

Investments

₹1,525 cr38%

Inventories

₹554 cr14%

Receivables

₹339 cr9%

Cash & equivalents

₹651 cr16%

Other assets

₹578 cr15%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Glaxosmithkline Pharmaceuticals Ltd.	42,773	2,524.80	83.0	22.74	27.4%

StoxGud checklist: Bullish setup · 7/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-4.1%

6 months+1.8%

1 year-4.5%

3Y CAGR+20.8%

5Y CAGR+8.6%

10Y CAGR+6.1%

50-day avg₹2,722.42

200-day avg₹2,516.84

RSI (14)46

Compare Glaxosmithkline Pharmaceuticals Ltd. with

Ipca Laboratories vs Glaxosmithkline Pharmaceuticals Glaxosmithkline Pharmaceuticals vs Emcure Pharmaceuticals Glaxosmithkline Pharmaceuticals vs Ajanta Pharmaceuticals Glaxosmithkline Pharmaceuticals vs Narayana Hrudayalaya Glaxosmithkline Pharmaceuticals vs Sai Life Sciences

FAQs

What is the share price of Glaxosmithkline Pharmaceuticals Ltd.?

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) closed at ₹2,524.80 on NSE on 06 Nov 2026.

What is the market cap of Glaxosmithkline Pharmaceuticals Ltd.?

₹42,773 crore at the latest close.

What is the P/E ratio of Glaxosmithkline Pharmaceuticals Ltd.?

83.0, on trailing-twelve-month earnings from its filings.

How fast is Glaxosmithkline Pharmaceuticals Ltd. growing?

Glaxosmithkline Pharmaceuticals Ltd.: revenue has compounded at 5.2% a year over three years; net profit at -15.1% a year. Latest-quarter revenue is up 20.8% year on year.

How profitable is Glaxosmithkline Pharmaceuticals Ltd.?

On a trailing-twelve-month basis return on equity is 27.4%, return on capital employed 82.8%, operating margin 34.1%, net margin 12.4%.

How much debt does Glaxosmithkline Pharmaceuticals Ltd. have?

Glaxosmithkline Pharmaceuticals Ltd. is debt-free: debt to equity is 0.00 with borrowings of ₹0 cr against cash of ₹651 cr (balance sheet of 2026-09-30). Operating profit covers interest 477.9 times.

Financials parsed from Glaxosmithkline Pharmaceuticals Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from JUN '19, annual from FY20, balance sheet from Mar '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.